Draft:Nyrada

Mechanism of action

Xolatryp is designed to inhibit TRPC-mediated calcium entry into cells. TRPC3/6/7 are calcium-permeable ion channels that may become activated during ischemia, oxidative stress, or mechanical injury, contributing to increased intracellular calcium levels.Excess intracellular calcium has been associated with mitochondrial dysfunction and cellular injury. By targeting these channels, the compound is intended to reduce calcium influx and limit downstream cellular damage.^[4]

Preclinical research

According to company-reported studies, Xolatryp has been evaluated in animal models of myocardial infarction, ischemic stroke, and traumatic brain injury. In rodent models of myocardial ischemia-reperfusion injury, treatment was associated with reductions in infarct size and arrhythmic events compared with controls.^[5]

In experimental stroke models, administration of the compound was reported to reduce tissue damage in the ischemic penumbra and to decrease biomarkers associated with neuronal injury.

The compound has also been studied in preclinical models of traumatic brain injury, including research conducted in collaboration with the U.S. Army's Walter Reed Army Institute of Research, where treatment was associated with reduced measures of secondary injury on imaging.^[6]

Phase I trial

Following completion of preclinical studies, Xolatryp entered first-in-human testing in 2025. The Phase I trial enrolled healthy adult volunteers and was conducted in Australia as a placebo-controlled, dose-escalation study designed to assess safety, tolerability, and pharmacokinetics.^[7]

In September 2025, the company reported that the study met its primary safety endpoints and that the compound was generally well tolerated across dose cohorts. No dose-limiting toxicities were reported. According to company disclosures, pharmacokinetic data indicated plasma concentrations consistent with preclinical modelling.^[4]

Phase II trial plans

As of late 2025, Nyrada disclosed plans to initiate a Phase IIa randomized, double-blind, placebo-controlled multicentre study in patients presenting with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). The proposed study is expected to enroll approximately 200 patients, pending regulatory and ethics approvals.^[4]

The trial is designed to evaluate safety and explore preliminary efficacy following intravenous administration shortly after reperfusion. Planned endpoints include infarct size measured by cardiac MRI, incidence of arrhythmic events, and biomarkers of cardiac injury. Follow-up assessments are intended to evaluate clinical outcomes and cardiac function.

Participating sites are expected to include multiple hospitals in Australia, with potential expansion to additional locations. The study represents the first planned evaluation of the compound in patients with acute myocardial infarction.

TRPC channels and calcium signalling

Transient Receptor Potential Canonical (TRPC) channels are a subgroup of TRP ion channels involved in the regulation of intracellular calcium (Ca2+) homeostasis. These channels are activated by receptor stimulation, mechanical stress, and oxidative signals, allowing calcium ions to enter cells. TRPC3, TRPC6, and TRPC7 are expressed in cardiovascular and nervous system tissues and have been studied for their role in pathological calcium signalling during ischemia and reperfusion injury.^[8]

During ischemia-reperfusion injury, restoration of blood flow following a period of oxygen deprivation can result in abrupt increases in intracellular calcium concentration. Excess calcium influx has been associated with mitochondrial dysfunction, activation of proteolytic enzymes, oxidative stress, and initiation of apoptotic and necrotic cell death pathways. Experimental models have implicated TRPC-mediated calcium entry as one contributing factor in this process.^[9]

Similar mechanisms have been examined in models of ischemic stroke and traumatic brain injury, where secondary injury processes involving calcium dysregulation may expand tissue damage beyond the primary insult.

Experimental investigation of TRPC inhibition

Preclinical studies in animal models have investigated the effects of genetic deletion or pharmacological inhibition of TRPC3, TRPC6, and TRPC7 channels. In murine models of myocardial ischemia-reperfusion injury, deletion of these channels has been associated with reduced infarct size and improved functional recovery compared with wild-type controls.^[10]

Pharmacological inhibitors targeting TRPC channels have also been explored in models of cardiac hypertrophy, heart failure, and renal disease. These investigations have contributed to broader scientific interest in TRPC channels as potential therapeutic targets in cardiovascular and neurological disorders.